Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › H2020

PIBD-SETQuality · Paediatric Inflammatory Bowel Diseases Network for Safety, Efficacy, Treatment and Quality improvement of care

H2020Status: CLOSED1 January 201630 June 2021EU funding €5,996,000Call H2020-PHC-2014-2015

The incidence of paediatric onset Inflammatory Bowel Diseases (PIBD) has risen dramatically in recent decades. Compared to adult forms, PIBD reflects a more severe disease, more often requiring aggressive treatment with immunomodulators, and thereby exposing children to a life-long risk of serious disease and treatment-related adverse events, such as infections and malignancies. Therefore, there is an urgent need to develop strategies which balance, on an individual basis, therapeutic effectiveness with risks of treatment.The overall goal of this proposal is to develop and validate a treatment algorithm for PIBD based on high or low risk predictors for early complicated or relapsing disease. This will improve effectiveness, while reducing treatment related risks and life-long complications due to uncontrolled disease progression.To attain this goal 3 specific aims are proposed under the umbrella of an international network, the ""PIBD-net"": 1) Development of an accessible and feasible risk-stratified treatment algorithm for new onset paediatric IBD on an existing inception cohort and validation in an independent cohort2) Generation of a prospective large longterm real world inception cohort in a registry designed to analyze effectiveness and safety signals and correlate them to individual risk factors 3) Design and performance of a risk algorithm-based prospective large-scale multicenter randomized clinical trial (RCT) (stratification into high or low risk groups based on specific aim#1) in order to provide optimal personalized therapy : low risk azathioprine vx. methotrexate, high risk : methotrexate vx. adalimumabThis project will translate into the first risk-stratified PIBD treatment algorithms allowing optimization of medical therapy while minimizing treatment-related risk (personalized medicine).""

Consortium · 14 organisations

coordinator

UNIVERSITE PARIS CITE

FR · €580,000

participant

GREATER GLASGOW HEALTH BOARD

UK · €431,459

participant

LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

DE · €120,895

participant

DEUTSCHE MORBUS CROHN/COLITIS ULCEROSA VEREINIGUNG BUNDESVERBAND FUR CHRONISCH ENTZUNDLICHE ERKRANKUNGENDES VERDAUUNGSTRAKTES (DCCV) EV

DE · €33,750

participant

VRIJE UNIVERSITEIT BRUSSEL

BE · €259,720

participant

AIMES GRID SERVICES COMMUNITY INTEREST COMPANY

UK · €51,375

participant

VIB VZW

BE · €150,000

participant

SHAARE ZEDEK MEDICAL CENTER

IL · €427,339

participant

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

NL · €682,980

participant

QUEEN MARY UNIVERSITY OF LONDON

UK · €331,750

participant

THE FOUNDATION FOR MEDICAL RESEARCH AND DEVELOPMENT OF INFRASTRUCTURES AND HEALTHCARE SERVICES BY THE E WOLSFON MEDICAL CENTER

IL · €176,612

participant

AIMES MANAGEMENT SERVICES LIMITED

UK · €17,375

participant

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

IT · €192,862

participant

PEDIATRIC INFLAMATORY BOWEL DISEASES NETWORK PIBD-NET

FR · €2,539,882

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.